American Academy of Dermatology

Combination aesthetic treatments often lead to superior results. Here are four tips from the 2018 AAD Summer Meeting.

In this article, Dr. Norman Levine sums up his takeaways from the American Academy of Dermatology annual meeting, beginning with a presentation by two physicians who addressed the difficulties of managing hidradenitis suppurativa, such as fixed dosing. He also addressed controversies associated with treatments for atopic dermatitis. Apparently, bleach baths are no better than regular baths in improving skin symptoms.

Physicians weigh in expectations for new developments within all facets of dermatology from pediatric dermatology to dermatopathology.

Initial results of an investigator-initiated phase 4 trial suggest that blocking interleukin-12 (IL-12) and IL-23 may reduce cardiovascular inflammation associated with psoriasis, researchers reported at AAD 2018.

Diagnosing PRP is challenging because it can mimic eczema, psoriasis, or even ichthyosis. Biologic treatment for refractory cases considered, researchers said at AAD 2018.

While the vast majority of basal cell carcinomas are treated and resolved with surgery, systemic therapy with one of the two hedgehog pathway inhibitors could be a treatment option for unresectable or metastasized disease, researchers reported at the American Academy of Dermatology annual meeting in San Diego this week.

Injectable aesthetic products recently FDA-approved or in late stages of development include polycaprolactone, a new hyaluronic acid and multiple neuromodulators.

The transgender dermatology patient may face a unique set of challenges doctors should be prepared to address, says Dr. Brian Ginsberg.

With one approved biologic available and many more under investigation, the future of treatment for hidradenitis suppurativa looks very promising.

Speaking at the American Academy of Dermatology annual meeting in February, Dr. Brett Coldiron described challenges dermatologists should be prepared for this year, including Medicare payment reductions, insurers' cost-saving strategies and practice consolidations.

Not all biologic treatments are equal. Side effects, effectiveness, cost and administration style are among factors physicians should consider when switching treatments, experts report at AAD 2018.

This week during the annual meeting of the American Academy of Dermatology in San Diego, Robert Sidbury, M.D., addressed developments in atopic dermatitis treatments since the publication of treatment guidelines in 2014.

During the American Academy of Dermatology’s annual meeting, physicians addressed the monumental changes that have occurred since the advent of biologic therapy for systemic autoimmune conditions, such as psoriasis and atopic dermatitis. Today, some patients are able to achieve complete disease clearance. Although there may be viable treatments for these conditions, access to care and medication adherence remain top issues, physicians say.

Combination treatments to reduce scarring have been shown to be effective without the need for aggressive surgical techniques that can lead to suboptimal results, researchers reported at AAD 2018 this week.

Multidisciplinary skin cancer care is an approach that might not only improve patient outcomes, but also professional satisfaction, researchers reported at AAD 2018 this week in San Diego.

There's been much debate in the literature about the need for and role of vitamin D, which may encourage patients to overdo vitamin dosing, researchers said at AAD 2018 this week.

Female patients with hormonal acne that typically flares before or after menstrual cycles may be ideal candidates for spironolactone, said Emmy M. Graber, M.D., president of the Dermatology Institute of Boston who spoke at AAD 2018 in San Diego this week.

Systemic disease among patients with discoid lupus erythematosus, a chronic form of cutaneous lupus, can develop within one to two years of initial diagnosis, says Joseph F. Merola, M.D., reporting at the American Academy of Dermatology annual meeting in San Diego.

Dermatology Times will be reporting from the AAD annual meeting this week in San Diego. Visit our conference news page to follow the developments from the meeting.

The American Academy of Dermatology annual meeting - Feb. 16-20 in San Diego - will highlight the status of new systemic treatments for chronic skin conditions, such as moderate-to-severe atopic dermatitis and psoriasis; in addition to new treatments for inflammatory skin conditions. Bookmark this site to follow the developments.